We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Will Take Positive Phase 3 Interim Data on ATTR Drug to FDA
AstraZeneca Will Take Positive Phase 3 Interim Data on ATTR Drug to FDA
With positive new phase 3 interim results in hand, AstraZeneca is poised to file for regulatory approval for eplontersen, an antisense drug to treat complications of transthyretin amyloidosis (ATTR), a rare and fatal disease.